Clinical Trials
12 trialsNCT06756035 2026-06-04
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT05568680 2026-05-12
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
Phase 1 Recruiting
NCT06251310 2026-05-08
SW-682 in Advanced Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Recruiting
NCT07443020 2026-04-07
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT07277413 2026-04-03
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT06566079 2026-02-17
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Recruiting
NCT07192900 2026-01-15
(RIOT 4A)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT03760575 2025-12-04
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT03917043 2025-06-18
APG-2449 in Patients With Advanced Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT05304208 2025-04-25
ENSURE
Erasmus Medical Center
Phase 1 Recruiting
NCT06726564 2024-12-10
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1 Recruiting